Development of In Vitro Diagnostics for Biodefense, Antimicrobial Resistant Infections, and Emerging Infectious Diseases
$2,443,961N01FY2024AINIH
Clear Labs, Inc., Menlo Park CA
Investigators
Abstract
To support the development of promising diagnostics technologies for biothreat pathogens and toxins, as well as pathogens causing emerging and reemerging infectious diseases. Areas of support may focus on improving performance of agnostic nucleic acid sequencing solutions on commercial platforms; methods that improve protein analyte detection; and efforts to improve direct-from-blood or other biofluid detection and identification of microbial infection.
View original record on NIH RePORTER →